We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

15 hedge funds and large institutions have $36.6M invested in Barinthus Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

24% more capital invested

Capital invested by funds: $29.5M → $36.6M (+$7.07M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.78% less ownership

Funds ownership: 26.02% → 25.24% (-0.78%)

6% less funds holding

Funds holding: 16 → 15 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
1
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$39.6K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.1K
3
Renaissance Technologies
Renaissance Technologies
New York
+$28K
4
UBS Group
UBS Group
Switzerland
+$4.92K

Top Sellers

Rank Fund Capital Flow
1
IIM
Ipswich Investment Management
Massachusetts
-$13.5K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$3K
3
TRCT
Tower Research Capital (TRC)
New York
-$309
Name Holding Trade Value Shares
Change 		Change in
Stake
MGIM
1
M&G Investment Management
United Kingdom
$20.8M – – –
AI
2
Alphabet Inc
California
$5.59M – – –
HH
3
HSG Holding
Hong Kong
$4.3M – – –
DF
4
DC Funds
Virginia
$2.37M – – –
BCM
5
BlueCrest Capital Management
Jersey
$2M – – –
Baird Financial Group
6
Baird Financial Group
Wisconsin
$724K – – –
JHU
7
Johns Hopkins University
Maryland
$398K – – –
Morgan Stanley
8
Morgan Stanley
New York
$122K +$39.6K +11,719 +55%
Renaissance Technologies
9
Renaissance Technologies
New York
$110K +$28K +8,299 +39%
IIM
10
Ipswich Investment Management
Massachusetts
$85.1K -$13.5K -4,000 -15%
Janney Montgomery Scott
11
Janney Montgomery Scott
Pennsylvania
$55K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$41.2K +$39.1K +11,568 New
UBS Group
13
UBS Group
Switzerland
$5.71K +$4.92K +1,458 +1,638%
NECFA
14
New England Capital Financial Advisors
Connecticut
$384 – – –
RhumbLine Advisers
15
RhumbLine Advisers
Massachusetts
$213 – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$3K -1,000 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$309 -100 Closed

BRNS Hedge Fund Activity: Q4 2023 in Review

15 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2023, worth a combined $36.6M — up 24% from $29.5M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BRNS and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $39.6K. The largest seller was Ipswich Investment Management, cutting an estimated $13.5K.

  • 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2023, down from 16 in Q3 2023.
  • Funds reported $36.6M of Barinthus Biotherapeutics stock for Q4 2023, up 24% quarter-over-quarter.
  • 1 fund opened new Barinthus Biotherapeutics positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest Barinthus Biotherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $39.6K added.
  • The largest Barinthus Biotherapeutics seller in Q4 2023 was Ipswich Investment Management, an estimated $13.5K sold.

Based on aggregated 13F filings for Q4 2023.